(Q35771142)

10 August 2017

title

Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? (English)

1 reference

10 August 2017

Maria Theodoulou

1

1 reference

10 August 2017

Clifford Hudis

series ordinal

2

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

100

1 reference

10 August 2017

issue

10

1 reference

10 August 2017

page(s)

2052-2063

1 reference

Risk factors for doxorubicin-induced congestive heart failure

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Anthracyclines in the treatment of gynecologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Anthracyclines in the treatment of cancer. An overview

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Anthracycline-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Cardiotoxicity of adriamycin and related anthracyclines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Cardiac safety of liposomal anthracyclines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20207

7 January 2021

Identifiers

DOI

10.1002/CNCR.20207

1 reference

10 August 2017

1 reference